2-benzyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-Indazole → HCID 58529603, compound

Participants

Reaction Steps

Using the procedures described in Steps 1-6 of Intermediate SS and substituting 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ol-2-benzyl-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (1:1) for Intermediate C, 5-(2-benzyl-3-methyl-2H-indazol-6-yl)-7-piperidin-3-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine hydrochloride was prepared. The salt was dissolved in 3:1 CHCl3/isopropanol (25 mL). The mixture was washed with saturated, aqueous NaHCO3 (25 mL), brine, dried (Na2SO4) and concentrated to dryness to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ 7.89 (s, 1 H), 7.76 (d, 1 H), 7.53 (s, 1 H), 7.24-7.38 (m, 3 H), 7.21 (d, 2 H), 7.08 (dd, 1 H), 6.58 (s, 1 H), 5.64 (s, 2 H), 3.14-3.30 (m, 3H,) 2.93 (d, 1 H), 2.62 (s, 3 H), 2.50-2.59 (m, 1 H), 2.01-2.11 (m, 1 H), 1.43-1.70 (m, 3 H); ES-MS m/z 438.39 [M+H]+, HPLC RT (min) 2.10.

Provenance & Evidence